RESEARCH MONOGRAPH · KDC-MN-096

Metformin

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

81/100

Cheap, old, AMPK-adjacent, and probably less of a geroprotector than the longevity scene wants

Here's the thing with metformin. It's one of the best-studied small molecules in human medicine, full stop. Decades of T2D data, hundreds of millions of patient-years of safety, mechanism that crosses AMPK activation, mitochondrial complex I partial inhibition, gut microbiome shifts, and a probable reduction in hepatic gluconeogenesis. The diabetes story is rock solid. The longevity story is more interesting than it is conclusive.

The hype came largely from the Bannister observational study showing diabetics on metformin had lower all-cause mortality than non-diabetics, which is a startling result but also a textbook setup for confounding. The TAME trial design from Barzilai is the real thing to watch, but readout is years out and theres real argument about endpoints. Meanwhile the MASTERS trial showed metformin actually blunted the strength and hypertrophy response to resistance training in older adults. Thats a finding the longevity scene mostly ignored.

Mechanism is well-mapped where it matters for glucose control, less clear where it matters for aging. Complex I partial inhibition is real (we've got the cryo-EM structures now), but whether thats the relevant geroscience hit or whether it's the AMPK-LKB1 axis or microbiome-mediated, honestly nobody has cleanly nailed it. The mitohormesis story is plausible and the autophagy connection is there, but the magnitudes in non-diabetic populations look modest.

What we like is the safety floor. B12 depletion is real and worth tracking, lactic acidosis risk is essentially zero in people with intact renal function, and the cost is trivial. As a research molecule it's reliable, it's reproducible, and the literature is huge.

What we dont like is the cargo-cult treatment. The blanket assumption that everyone benefits from metformin ignores the resistance-training data, ignores responder heterogeneity, and ignores that the strongest mortality signal is in diabetic populations where you'd expect it.

Honestly we think metformin will hold up as a legitimate metabolic tool with modest geroprotective signal in subpopulations, not as the universal age-slowing drug some people sold it as. Sourcing is pharmacopoeia grade and trivially cheap. Keep it in the toolbox, dont mistake it for rapamycin.

Evidence: 88
Mechanism: 78
Reliability: 72
Safety: 90
Sourcing: 95
Value: 92
Signal: 60
Staying power: 75

Plain-language summary Intrigue 85 / 100

Metformin, sold as Glucophage, is the most prescribed diabetes drug in the world. Beyond glucose control, it has emerging interest in longevity; the TAME trial is investigating whether metformin slows aging in humans. The mechanism involves AMPK activation and mTOR inhibition. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Biguanide / AMPK activator

A first-line type 2 diabetes biguanide derived from French lilac (Galega officinalis), increasingly investigated for longevity and cancer prevention applications.

Abstract

Metformin (Glucophage; 1,1-dimethylbiguanide; CAS 657-24-9; molecular formula C4H11N5; molecular weight 129.16) is a biguanide derived from guanidine, originally identified in the 1920s from the French lilac (Galega officinalis) and approved in Europe in 1957 and the United States in 1995 for type 2 diabetes. The compound is the most prescribed oral antihyperglycemic globally. Primary mechanism is mild inhibition of mitochondrial complex I producing AMPK activation, with downstream reduction in hepatic gluconeogenesis, improved insulin sensitivity in skeletal muscle, and reduced gut glucose absorption. Beyond diabetes management, metformin has accumulated evidence in cancer prevention (reduced incidence in diabetics), cardiovascular outcomes (UKPDS, in obese diabetics), and possible longevity effects. The TAME trial (Targeting Aging with Metformin) is investigating longevity endpoints in non-diabetic populations. Pharmacokinetics: plasma half-life 4 to 9 hours; oral bioavailability 50 to 60 percent; renally excreted unchanged. Reported research dose ranges in the literature span roughly 500 to 2550 mg, typically in divided portions. Lactic acidosis is the principal serious adverse event but is rare with appropriate renal function monitoring.

Mechanism of action

Mild complex I inhibition with AMPK activation. Reduces hepatic gluconeogenesis, improves muscle insulin sensitivity, reduces gut glucose absorption.

Reported research dose ranges

500 to 2550 mg, typically in divided portions (reported research dose ranges in the literature).

References

UKPDS 34: Effect of intensive blood-glucose control with metformin. Lancet 1998.
Barzilai N, et al. Metformin as a tool to target aging. Cell Metab 2016.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-096

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Metformin

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs